Drug Approval | October 14, 2021
IOL receives Korean FDA approval
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
In collaboration with RAND Europe, the Vitality calculator predicts an individual's healthspan and future health risks
The drug is being developed at lab scale for the first-line of treatment of Covid-19
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
VIPER AI solutions support care teams by automating the identification of potentially eligible patients at the time of diagnosis and easily matching them to relevant trials
The Pune centre expands its presence beyond Bangalore and Hyderabad
The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Quantitative restrictions in place to meet domestic needs to cater to the vaccination programme
Subscribe To Our Newsletter & Stay Updated
